Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 13th European Diabetes and Endocrinology Congress Dublin, Ireland.

Day 1 :

Keynote Forum

Gerald C. Hsu

eclaireMD Foundation, USA

Keynote: Dr
Conference Series Euro Endocrinology 2018 International Conference Keynote Speaker Gerald C. Hsu photo
Biography:

Abstract:

Keynote Forum

J Shen

Immunological Genetics and HLA Typing, China

Keynote: Dr
Conference Series Euro Endocrinology 2018 International Conference Keynote Speaker J Shen photo
Biography:

Jie Shen, is the Chief Physician for The center of immunological genetics and HLA typing (CDMP data bank lab for Jiangsu Province), He is the Chief Physician for the Department of Endocrinology and Metabolism, Jiangsu Province Hospital (First Affi liated Hospital of Nanjing Medical University). He did postdoctoral fellowship at the Phoenix Epidemiology and Clinical Research Branch, NIDDK, NIH, in Phoenix, Arizona. Currently he is doing research for Epigenetic Regulation on Obesity and Type 2 Diabetes, Epidemiology Study on Chinese Population, HLA Typing and HLA Related Diseases Research and Clinical Practice on Endocrine and Metabolic Diseases.

Abstract:

Background and Aims: Large-scale epidemiologic studies to assess the increased prevalence of obesity in China, and relate this increase to economic development, are lacking. In 2001, the China Marrow Donor Program (CMDP) began collecting anthropometric data on volunteers and information on >1.8 million individuals from 31 branch registries are currently available. Materials and methods: CMDP data from 1,163,094 healthy adults examined in years 2004-2013 were included in a cross-sectional analysis to estimate the yearly prevalence of obesity and overweight. The annual per capita Gross Domestic Product (GDP) was used to evaluate the relationship between economic growth and obesity. AII statistical analyses were conducted with the use of SAS for Windows version 9.2 software (Research Triangle Institute). Approximate power calculations were performed using StatCalc (Sample Size and Power for Population Survey) in Epi Info version 7 (National Cancer Institute, USA), assuming a survey design effect of l.5. The sample sizes for the groups with the smallest sample size were sufficient to estimate the prevalence with confidence limit of 0.05 with more than 80% power; most of the estimates can achieve more than 90% power.
 
Results: In 2013, the age and sex-standardized prevalence of obesity and overweight among Chinese adults was 10.16% and 32.40%, affecting 86.10 and 257.38 million individuals, respectively.
 
The prevalence of obesity and overweight increased with increasing age and were higher in males (13.08% and 38.66%) as compared to females (7.48% and 22.81%). From 2004 until 2013, the prevalence of obesity increased from 6.38% t0 10.16% where the increase was greater from 2011- 2014 as compared to 2004-2010. Females had a greater increase in recent years as compared to males, suggesting that differences by gender are becoming smaller.

 

Keynote Forum

Pierre Lefebvre

The University of Liège, Belgium

Keynote: Dr
Conference Series Euro Endocrinology 2018 International Conference Keynote Speaker Pierre Lefebvre photo
Biography:

Pierre J Lefebvre received his MD Degree at the University of Liège, Belgium P. Lefebvre has published more than 25 books and 900 papers. He serves or has served on the Editorial Board of more than 20 International Journals. He has been recognised by several awards including the Masius Award (University of Liège, 1965), the University Foundation Alumni Award (Brussels, 1968), the Pfi zer Award (Royal Academy of Medicine, Belgium 1979), the Claude Bernard Award (European Association for the Study of Diabetes, 1984), the Maurice Dérot Award (Paris, 1987) the Paul Langerhans Award (Deutsche Diabetes Gesellschaft, 1992), the Mizuno Award (Tokyo, 1996), the Novartis Long-Standing Achievement in Diabetes Award (2000), the Harold Rifkin Award of the American Diabetes Association (2012) etc. He has given the Alexander Marble (Boston, 1993), the Celal Oker (Istanbul, 1993) and the Banting Memorial (Diabetes UK, 2001) Lectures.

Abstract:

Absolute or relative hyperglucagonemia has been recognized for years in all experimental or clinical forms of diabetes. It has been
suggested that excess secretion of glucagon by the islet α cells is a direct consequence of intra-islet insulin secretory defects. Recent studies have shown that knockout of the glucagon receptor or administration of a monoclonal specific glucagon receptor antibody
make insulin-deficient type 1 diabetic rodents thrive without insulin. These observations suggest that glucagon plays an essential role in the pathophysiology of diabetes and that targeting the α cell and glucagon are innovative approaches in the management of diabetes. Despite active research and identification of promising compounds, no one selective glucagon antagonist is presently used in the treatment of diabetes. Interestingly, besides insulin, several drugs used today in the management of diabetes appear to exert their effects, in part, by inhibiting glucagon secretion (glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, α-glucosidase inhibitors and, possibly, sulphonylureas) or glucagon action (metformin). The potential risks associated with total glucagon suppression include α-cell hyperplasia, increased mass of the pancreas, increased susceptibility to hepatosteatosis and hepatocellular injury and increased risk of hypoglycaemia, and these should be considered in the search and development of new compounds reducing glucagon receptor signaling. More than 40 years after its initial description, hyperglucagonaemia in diabetes can no longer be ignored or minimized, and its correction represents an attractive way to improve diabetes management.

  • Endocrinology and Metabolism, Obesity and Metabolism, Diabetes Therapeutics and Diagnostics
Location: Library Suite
Speaker

Chair

Pierre Lefebvre

The University of Liège, Belgium

Speaker

Co-Chair

Gerald C Hsu

eclaireMD Foundation, USA